Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States
Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Posted by SkinDoc on Friday, November 6, 2009, at 8:20 pm. Filed under Skin Care News. Tagged Adult Patients, Astellas Pharma Us, Astellas Pharma Us Inc, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gram Positive Bacteria, Launch, Mrsa, Nasdaq, September 11, Skin And Skin, Skin Structure Infections, Staphylococcus Aureus, Strains, Telavancin, Theravance Inc, Thrx, United States.
Both comments and trackbacks are currently closed.
